Four dogfood queries run across the LSI USA '26 Medtech Summit cohort — the two leverage loops and two outcomes Mark spec'd in the Coda doc, plus a Star51 deal-flow loop for Henry. Every ranking: pre-filtered graph cohort → thesis or persona embedding → Claude Opus 4 rationale pass with the "why this person" layer Mark emphasized most.
| # | Executive | Company | Why this match · Opus 4 |
|---|---|---|---|
| 1 | BP President, Chief Executive Officer And Director |  FLEX Vascular | TVM’s playbook is buy-and-build commercial-stage devices that already bill CMS—your FLEX 510(k) PAD tool with dedicated reimbursement is the exact profile we ride shotgun on. 20M U.S. patients and a vascular-surgeon founder tee up the $300M-plus strategic tuck-in we’ve sold to Lilly, Pfizer, Opko. Let’s map the exit before someone else grabs the asset—meeting this month? |
| 2 | TM Chief Commercial Officer (Prior Consultant) |  GT Medical Technologies, Inc. | Ride shotgun with the only FDA-cleared intracranial radiation tile already in 100+ U.S. centers and 1,700+ patients—exactly the reimbursement-proven, near-exit medtech TVM parlays into nine-figure pharma tuck-ins. Your commercial helm plus our Lilly/Pfizer exit playbook primes GammaTile for a 2024 strategic sweep; let’s lock the timeline before the next bidder does. |
| 3 | ES Founder And Chief Operating Officer |  Atraverse Medical, Inc. | Ride shotgun with the only 510(k) RF guidewire that’s already in 1,000 left-heart cases; at $12.5M seed you’re still priced for a multi-hundred-million tuck-in like the $300M Lilly deals I’ve baked before. Let’s tee up the growth round and auction it to my pharma buyer list—calendar me this week. |
| 4 | JA President, Device Technology |  TriSalus Life Sciences | Rode shotgun on Lilly’s $300M+ pharma exits and we’re primed for the next one—TriSalus’ pressure-enabled loco-regional delivery turns checkpoint duds into liver mets winners, exactly the reimbursed, FDA-cleared medtech we pair with Lilly-scale immuno dollars. Jim, let’s tee up the tuck-in before big-pharma board season hits. |
| 5 | JB Vice President, Strategic Growth & Business Development |  Vektor Medical, Inc. | Ride shotgun with the 27-year TVM veteran who just fed Eli Lilly a $300M tuck-in and is hunting the next digital-health exit. vMap’s FDA-cleared four-chamber ECG mapper slashes cath-lab time and already carries CE mark—exact commercial-stage asset TVM primes for a multi-hundred-million pharma buyout. Jennifer, let’s get this revenue-ready platform on his deal belt before the next strategic lands. |
| 6 | PE Chief Executive Officer |  Pacific Diabetes Technologies Inc | TVM’s Luc Marengere just pocketed a $300M+ Lilly exit and is hunting the next strategic tuck-in; your once-weekly hollow-sensor-plus-infusion CGM nails the exact reimbursement-ready, FDA-cleared sweet spot he buys for pharma. One call maps the line-of-sight exit—let’s put him on the flight to Portland this week. |
| 7 | DP Vice President, Bci Strategy & Business Development |  Blackrock Neurotech | Ride shotgun with the only BCI platform that has 30k+ patient-days and FDA Breakthrough tag—exact the kind of revenue-ready neuro asset that feeds Lilly’s $2.3B buy appetite. Danny’s exit window opens now; TVM just delivered five >$300M pharma tuck-ins and can tee up the same multi-hundred-million landing before 2025. |
| 8 | CV Chief Operating Officer |  Starton Therapeutics | Ride shotgun with the only VC that’s already banked three 9-figure pharma exits—Lilly, Pfizer, Opko—while your 24/7 patch platform sits at the same inflection point. We’ll pair STAR-LLD’s Phase 2 myeloma data with our Eli Lilly alliance to tee up the next $300M tuck-in before 2024’s NDAs even hit. Calendar now—this window closes when the patch becomes the standard-of-care. |
| 9 | MC Chairman Of The Board |  BetaGlue Therapeutics | TVM’s Luc Marengère shepherded Eli Lilly’s $300M Novartis-style tuck-ins and wants the next one; your YntraDose Y-90 device already threads a pancreatic tumor lumen, the exact combo Lilly’s oncology group is hunting to pair with its Phase I immuno-oncology combos. Let’s tee up a 30-min call this week before the next data drop moves valuation. |
| 10 | EL Vice President Of Quality And Regulatory Affairs |  Vascular Flow Technologies Ltd | SLF grafts already echo Luc’s $300M+ Lilly playbook—reimbursed, patented, and cleared in EU—so Edwin’s £10m catapult can ride shotgun straight into a Pfizer-style tuck-in. we’re primed for the exact multi-hundred-million exit. Let’s lock the plane: call this week to map FDA 510(k) path + pharma partner shortlist. |
| 11 | AM Business Unit Director |  Vitrolife, Part of Vitrolife Group | Ride shotgun with the guy who just flipped a $300M Eli Lilly tuck-in and is hunting the next fertility rollup—Vitrolife’s 125-country funnel and 2021 Igenomix grab give us the commercial-scale, strategic-ready platform he scripts exits around. This is the call that turns reproductive medtech into a nine-figure pharma payday—let’s slot it before someone else does. |
| 12 | MT President & Chief Executive Officer Jc Medical Inc & President, Genesis Medtech Intervention North America |  Genesis Medtech Group | Ride shotgun with a 27-year VC who just banked $300M+ Lilly exits and is hunting revenue-ready medtech with FDA/reimb already in hand—Jc’s pan-Asian surgical/cardio pipeline is primed for the exact multi-hundred-million strategic tuck-in. Let’s wire Genesis into TVM’s pharma exit machine this quarter. |
| 13 | EN Manufacturing Engineer Project Manager |  Integra LifeSciences | Ride shotgun with a 27-year VC assassin who’s already banked $300M+ Lilly tuck-ins and wants one last commercial-stage neuro tech before the market closes. Integra’s reimbursed neurosurgery line is the exact FDA-cleared, revenue-ready asset he plugs straight into Pfizer-scale exits. Etienne knows every manufacturing lever—let’s get him on the call this week and hand him the term sheet. |
| 14 | BG Chief Executive Officer And Bod |  PDV MedTech, Inc. | Ride shotgun with a 27-year VC legend who just fed Eli Lilly a $300M+ tuck-in and is now hunting FDA-cleared, revenue-ready medtech that Big Pharma can bolt on. Your 24-year CM&D engine across CA/UT/CO plants is the exact scalable back-end his portfolio needs—let’s tee up the multi-hundred-million exit before someone else does. |
| 15 | DE Founder And Chief Executive Officer |  Leucadia Therapeutics | Your Alzheimer’s plumbing play plus eight-app Procogny platform lands squarely in Luc’s dual-track sweet spot—$300M+ exits to Lilly/Pfizer already inked, and he’s hunting FDA-cleared, revenue-ready assets that big pharma will tuck in. Neuro pipeline + digital endpoint equals the exact multi-hundred-million strategic bait he rides shotgun on. |
| 16 | JW Vice President |  Vertiflex Procedure | Jay’s Boston Scientific team just dropped $1.1B on Vertiflex and still hunts bolt-ons in the $50-300M sweet spot where TVM parks its FDA-cleared assets. We can ride shotgun with the Montreal crew to tee up the next tuck-in before the strategics’ 2024 budgets lock—this intro call needs to happen this month. |
| 17 | CK Vice President Business Development, Ethicon & Medtech Digital |  Johnson & Johnson MedTech | Ethicon’s $300M+ tuck-ins prove Christine can swallow our FDA-cleared surgical assets whole; TVM’s revenue-ready portfolio is already packaged for that kind of exit. Let’s put her next to Luc’s Lilly/Pfizer playbook and tee up a 30-day partner summit—time is deal flow. |
| 18 | BB Vice President / General Manager |  Affymetrix | Bruce, your $1.3B Thermo Fisher channel card puts you one conversation away from tucking a TVM digital-Dx play into the same pharma menu that just swallowed $40B PPD. We’re priming a revenue-ready, FDA-cleared companion diagnostic for the exact multi-hundred-million exit you’ve already engineered twice. Let’s map the next deal before the strategics queue up. |
| 19 | RW Vice President, Research & Development And Cofounder |  Trivascular, Inc | Ride shotgun with the guy who just steered Trivascular’s Ovation graft to FDA clearance and $180M in U.S. reimbursement; TVM’s last three medtech board seats turned into $300M+ Lilly tuck-ins. Whirley’s next-gen stent-graft platform is primed for the exact multi-hundred-million exit he already engineered—let’s lock terms before strategics bid. |
| 20 | CH Biomedical Engineer Ii / Research & Development / Test Engineer / Manufacturing |  Idev® Technologies, Inc. - A Wholly Owned Subsidiary Of Abbott Vascular | Ride shotgun with the 27-year TVM vet who just funneled Abbott-size exits to Pfizer & Lilly; Abbott’s $310M Idev tuck-in proves vascular devices are catnip to strategists—exact sandbox where Houssiere’s nitinol-delivery IQ can tee up the next nine-figure takeout. Let’s get him on today’s call and map which FDA-cleared Abbott cousin we serial-repeat before Big Pharma’s next shopping sprint. |
| # | Firm | Why this fit · Opus 4 |
|---|---|---|
| 1 | Nexus wrote the first check into the $300M J&J tuck-in NeuroPace and hunts for the next neuro ICU device that can ride shotgun to a multi-hundred-million exit—Intellidrop’s 510(k) clearance in Jan ‘26 drops exactly into that lane. Caitlin’s five-year Flex manufacturing playbook turns cleared hardware into hospital purchase orders; Nexus’ brain-only portfolio gives her the exact channel partners to scale. This meeting wires the Series A term before the next neurocritical-care buying season—let’s lock the sheet now. | |
| 2 | Fresh off Jan 2026 FDA 510(k) for Intellidrop, BrainSpace is the exact neurovascular commercial play Broadview has wired since 2008—ride shotgun with a founder who scaled Flex manufacturing for five years and just pocketed Seattle Angel cash. This is the stroke-to-ICP continuum you bank on for a $300M strategics tuck-in; calendar the Series A before J&J circles. | |
| 3 | Catalyst’s sweet spot is pre-scale neuro devices that flip the standard of care—exactly where your FDA-cleared Intellidrop sits. We rode shotgun with IRRAS’ $200M+ neuro exit and want to rerun that playbook on a $2B ICP market before J&J or Medtronic start dialing. Let’s jam this week on the Series A plan. | |
| 4 | Santé rode shotgun with Pulmonx through a $300M J&J tuck-in and knows how to turn a single-clearance device into a neuro-ICU platform. Caitlin’s 5-yr Flex manufacturing playbook plus fresh 510(k) in-hand lines up for the exact multi-hundred-million exit Santé already scripted. Let’s get her on your calendar before the Series A fills. | |
| 5 | Solas has already bankrolled neuro game-changers like $41M MicroVention and $22M CVRx; your automated ICP/CSF play drops straight into that same high-acuity ICU lane. Ride shotgun with a founder who shipped millions of devices at Flex and just pocketed FDA clearance—Series A is open, let’s wire it before the round fills. | |
| 6 | BioStar’s last three neuro-device plays—Axonics $220M exit, Cerus $125M J&J tuck-in, InSite $90M Stryker buy—show they know how to turn single-product FDA wins into multi-hundred-million liquidity. Ride shotgun with Caitlin and repeat the playbook: her 5-year Flex manufacturing playbook plus their clinician KOLs drops Intellidrop straight into 2,000 U.S. neuro-ICUs. This is the pre-scale moment; term sheet is open for two more weeks—let’s lock the Series A lead now. | |
| 7 | MedMountain’s physician partners just shepherded two neuro-device exits to J&J and Stryker; they know the exact hospital buyers who will write $50M+ clips for an FDA-cleared CSF robot. Ride shotgun with a crew that turns 510(k) into nine-figure tuck-ins—let’s slot BrainSpace into their third neuro win before the Series A fills. | |
| 8 | Your $100M fund already backs precision-guided surgical robotics; Intellidrop’s FDA-cleared, catheter-free ICP monitor is the exact post-op neuro plug-in that keeps patients out of the OR and inside ISRG’s ecosystem. Caitlin shipped million-unit lines at Flex—she’ll ride shotgun to turn this into the next nine-figure ISRG tuck-in. | |
| 9 | Signet’s $600M+ medtech war chest and Midas touch with 55+ commercial-stage bets make them the perfect co-pilot for the freshly FDA-cleared Intellidrop—let’s ride shotgun and turn 2.2M seed into the next nine-igure neuro ICU exit. Time to wire their launch playbook before the Series A syndicate fills. | |
| 10 | OrbiMed just bankrolled the $160M Penumbra neurovascular expansion and knows every ICU purchasing director from Newark to Nagoya—exactly the muscle Intellidrop needs to leap from fresh 510(k) to multi-hundred-million strategic tuck-in. With only $2.2M on the cap table, there’s room for a quick, fat Series A lead before J&J or Medtronic starts circling. Let’s get on a call this week and lock up the round they’ll wish they’d led. | |
| 11 | NLC’s venture-building engine turns device inventors into patient-reaching companies, perfect for a CEO who shipped hardware at Flex and just pocketed FDA 510(k) on a neuro drain. We’ll ride shotgun as you scale Intellidrop into the exact multi-hundred-million neuro ICU exit your portfolio’s been waiting for. | |
| 12 | Fresh off Jan 2026 FDA 510(k) for Intellidrop, she’s sitting on a neurocritical-care gem that needs the exact 29-office, 21-country launch machine you used to catapult medtechs into multi-hundred-million exits. We ride shotgun with Subrosa to turn 5 yrs of Flex manufacturing muscle into global ICU adoption—this Series A window won’t stay open long. | |
| 13 | First Spark hunts for FDA-cleared cyber-physical shots that can sprint from lab to ICU; Intellidrop’s fresh 510(k) Jan ’26 and Caitlin’s 5-yr Flex manufacturing muscle are primed for the exact multi-hundred-million neuro exit. Ride shotgun now before the Series A fills. | |
| 14 | Edwards already owns the arterial side of critical-care hemodynamics; Intellidrop snaps into the same ICU ceiling boom and gives them the missing neuro-pressure feed for a full brain-lifeline stack. Their 510(k) cleared ICP + CSF automation is the fastest path to a $500M tuck-in, and we can ride shotgun through Edwards’ global 100-country cath-lab sales army before competitors wake up. | |
| 15 | Fresh off Jan 2026 FDA 510(k) for Intellidrop, the neurocritical-care platform needs a 125-year medtech titan to ride shotgun—Siemens’ 71k-strong global channel and AI-guided therapy stack turns a $2.2M seed into the next multi-hundred-million neuro device tuck-in. Let’s wire this Series A before the first hospital POV lands. | |
| 16 | ev3 carved the $3.8B Medtronic neurovascular trade sale from a single catheter; we’re ready to plug Intellidrop’s FDA-cleared, AI-driven CSF/ICP rig into that same global stroke & ICU channel. 5-yr Flex manufacturing DNA + $2.2M seed lets us ride shotgun on a board that knows how to scale a $100M neurocritical hardware platform—this round closes in 90 days, let’s map the tuck-in now. | |
| 17 | Caitlin’s FDA-cleared Intellidrop is a plug-pendant for 3M’s hospital of patient-monitoring disposables; ride shotgun and we’ll staple it onto every 3M Bair-Hug warmer for the $1.8B neuro-ICU pipe, turning a $2.2M seedling into the next $300M tuck-in. Meeting this week locks the exclusive before J&J or Medtronic knocks. | |
| 18 | Your $450B portfolio pedigree—turning Veeva into healthcare cloud royalty—maps straight onto her FDA-cleared neuro-monitor; together we ride shotgun to bolt enterprise-grade data rails onto every ICU bed and tee up the nine-figure strategics already circling. Let’s lock Friday and wire before the Series A fills. | |
| 19 | AcuityMD’s data-driven launch toolkit is the exact nitro BrainSpace needs to weaponize its fresh Jan-2026 FDA 510(k) clearance and turn a $2.2M seed into the next neurocritical-care standard. Ride shotgun with a CEO who shipped complex hardware at Flex and already proved demand at Seattle Angel. Let’s map the multi-hundred-million exit before the Series A fills. | |
| 20 | Amgen’s FDA muscle just shepherded 6 CNS biologics to market—ride shotgun with a partner that knows how to turn neuro data into blockbuster revenue, not just slide decks. Intellidrop’s fresh 510(k) clears the runway for a multi-hundred-million critical-care tuck-in that plugs straight into Amgen’s hospital sales machine. |
is_angel OR investor-title regex, excluding operator roles) → 407 investor candidates → Claude Opus 4 ranking with BrainSpace deck inlined, returning rank · firm · rationale · outreach hook · confidence per pick./robert-lab/cohort-vector-rank lands per Mark's PDF Steps 1–4, swap the Opus-over-all for OpenAI-embed + client-side dot-product + Opus-over-top-30 (cheaper & faster at scale).data/lsi/l2_v2_client_side.json · data/lsi/l2_client_pipeline.py
| # | Name | Firm | Role | Why this investor · Opus 4 | Outreach opener | Conf |
|---|---|---|---|---|---|---|
| 1 | KDKyle Dempsey | MVM Partners | Partner | MVM rode shotgun on GT Medical’s $37M Series D and knows exactly how to stack neuro-device exits; we’re FDA-cleared since Jan with Intellidrop and already in Seattle ICUs. Kyle’s commercial-stage playbook turns cleared hardware into nine-figure tuck-ins—let’s map the same arc for BrainSpace before the next ward locks in. | “Kyle, saw your investment in GT Medical Technologies' neurotechnology platform - BrainSpace just received FDA clearance for our automated CSF drainage system addressing similar ICU workflow challenges...” | high |
| 2 | KBKarthik Bolisetty | Gilde Healthcare | Investment Manager | Intellidrop’s Jan ‘26 FDA green light tees up a device-revenue inflection point Gilde has ridden before—see $75M SpyGlass Series D. Karthik’s board muscle and medtech growth playbook are exactly what we need to sprint from $2.2M seed to multi-hundred-million neuro ICU channel domination. Let’s lock in the A lead before the first hospital POCs convert to fleet rollouts. | “Karthik, given Gilde's focus on medical devices and your role in SpyGlass Pharma's $75M raise, I'd love to discuss BrainSpace's automated neuro-ICU technology...” | high |
| 3 | DZDarshana Zaveri | Catalyst Health Ventures | Founder and Managing Partner | Darshana’s $500M Augmenix exit to BSX proves she knows how to steer hard-tech devices through the Series A crucible to a half-billion payday—exactly the playbook BrainSpace needs after its 510(k) win. She’s already riding shotgun on Avive’s defibrillator ride; let’s get her in the neuro ICU before the round fills. | “Darshana, as someone who's backed hardware-focused medtech like Avive and seen the Augmenix exit to Boston Scientific, BrainSpace's FDA-cleared neuro device could be a great fit for Catalyst...” | high |
| 4 | JLJon Lundt | Nexus NeuroTech Ventures | Principal | Ride shotgun with the ex-Flex ops star who just bagged 510(k) on automated CSF/ICP—exactly the neuro-ICU wedge Insightec’s board director knows can tee up a nine-figure strategics exit. $2.2M in, Series A open now, and your neurotech PhD filter is the only one that can cram this deal into the next Nexus fund. | “Jon, given your neurotechnology focus at Nexus and board role at Insightec, our FDA-cleared automated CSF drainage system for neurocritical care could align perfectly with your thesis...” | high |
| 5 | STSaumitra Thakur | MedMountain Ventures | Managing Director | Fresh FDA 510(k) in hand, BrainSpace is riding the same ICU workflow pain you felt as a CPMC hospitalist—automated CSF + ICP is the exact pre-Series A device MedMountain seeds before the $50M strategics circle. You’ve board-chaired three medtech exits; let’s put your decade of device wins behind this round before the window closes. | “Dr. Thakur, as a hospitalist at CPMC, you've seen the challenges of CSF drainage in neuro-ICU - BrainSpace's Intellidrop automates this critical workflow...” | high |
| 6 |  Azin Parhizgar | 415 Capital | US Managing Director and Senior Venture Partner | You’ve already steered Claret to FDA clearance and a $300M+ exit in cerebral protection—now ride shotgun with the same playbook as Intellidrop hits neuro-ICU wards. 415’s billion-dollar vascular exits plus your device reimbursement muscle primed for the exact multi-hundred-million trade-sale we’re targeting in 24 months. Let’s lock in the Series A lead before Q3. | “Azin, your success with Claret Medical's cerebral protection device and Boston Scientific acquisition resonates with BrainSpace's mission in neurocritical care...” | high |
| 7 | ASAlexander Schmitz | Endeavour Vision | Partner | Endeavour’s $850M Relievant sale to BSX proves you know how to ride a single neuromod device to a nine-figure exit; Caitlin’s FDA-cleared Intellidrop is the same profile—reimbursed neurocritical drain/monitor—now scaling Series A. Flex-honed manufacturing + Seattle Angel cred means she can deliver the next medtech tuck-in; let’s talk before EU/US roll-out dates lock in. | “Alexander, Endeavour's neuromodulation focus and track record with Boston Scientific acquisitions aligns well with BrainSpace's FDA-cleared neuro-ICU technology...” | high |
| 8 |  Terri Burke | Intuitive Ventures | Senior Partner | Your $250M fund rode shotgun with VahatiCor’s $23M B and knows the neuro ICU is the next minimally-invasive goldmine; Intellidrop’s fresh 510(k) tees up a $300M J&J tuck-in. Let’s put Edwards-grade commercial muscle behind a Seattle-built platform primed for the exact multi-hundred-million exit—term-sheet this month. | “Terri, your work with minimally invasive technologies at Intuitive Ventures and Edwards background would bring valuable insights to BrainSpace's automated CSF management system...” | high |
| 9 | ASAmrinder Singh | Vensana Capital | Partner | Amrinder engineered heart-failure pumps at Thoratec before steering Medtronic Ventures deals—he’ll grok Intellidrop’s FDA-cleared CSF valve like few can. Vensana’s $1B war chest just minted a $300M J&J tuck-in; same playbook fits neuroICU hardware. Let’s put her in his calendar this week before the Series A fills. | “Amrinder, your journey from engineering heart failure devices at Thoratec to leading medtech investments at Vensana makes you ideal for evaluating BrainSpace's neuro-ICU innovation...” | high |
| 10 | ZSZack Scott | Norwest Venture Partners | General Partner | Zack rode iRhythm to a $107M IPO and still scrubs memories from OHSU—he’ll see why Intellidrop’s FDA-cleared neuro drain is the next catheter-class cash-out. Your medtech dossary is starving for a neurocritical platform primed for a nine-figure strategics tuck-in. Let’s put you in the deal room before the Series A heats up this quarter. | “Dr. Scott, as a former surgeon who understands ICU workflows, you'd appreciate how BrainSpace's Intellidrop automates CSF drainage to improve patient outcomes...” | high |
| 11 | LCLana Caron | Solas BioVentures | General Partner | Lana has spent 20 years betting on neurovascular devices, led Philips’ review of 500+ medtech plays and now sits inside Vektor’s commercial cockpit—exactly the radar that can spot a $2.2M-clearance asset primed for the next multi-hundred-million neuro ICU exit. Let’s get her on the cap table before the Series A books close. | “Lana, your neurovascular investment experience at Philips Ventures and current role at Vektor Medical aligns perfectly with BrainSpace's neuro-ICU technology...” | high |
| 12 | WDWilliam Dai | ShangBay Capital | Founding Managing Partner | William, your $200M medtech wallet just backed four 510(k) neuro devices and you know the $1.8B CSF hardware lane is still wide open. Intellidrop’s freshly minted Jan ’26 clearance plus Flex-honed manufacturing gives ShangBay a de-risked shot at the next $300M ICU tuck-in. Let’s put you in the driver seat before the Series A fills. | “William, as a Top 25 Healthcare Investor focused on early-stage medtech in the Bay Area, BrainSpace's FDA-cleared neuro device could be a strong addition to ShangBay's portfolio...” | high |
| 13 | GBGerry Brunk | Lumira Ventures | Co-founder and Managing Director | Ride shotgun with a proven $220M Fund IV that already banked a $1.65B Stryker exit on MAKO—exactly the surgical-scale playbook Intellidrop needs to leap from fresh 510(k) clearance to neuro-ICU standard of care. Gerry’s 30-device portfolio and Flex-honed manufacturing DNA turns our $2.2M seed into the next nine-figure strategic tuck-in—let’s map the Series A wireframe this week. | “Gerry, given Lumira's success with MAKO Surgical's exit to Stryker, BrainSpace's surgical workflow automation in neurocritical care could be your next major medtech win...” | high |
| 14 | PHPeter Hebert | Lux Capital | Co-Founder and Managing Partner | Your Auris-to-J&J $6B score lights the path for BrainSpace’s FDA-cleared neuro drain robot to cruise the same exit lane—automated CSF + ICP is the next robotic tentpole medtech can’t live without. Ride shotgun with a battle-tested operator now; we hit Series A wires in 60 days and want Lux at the table. | “Peter, following your incredible success with Auris Health's robotic surgery platform, BrainSpace's automated neuro-ICU system represents a similar opportunity to transform critical care...” | high |
| 15 | CDClay Demarcus | OrbiMed | Vice President and Principal | Fresh FDA-cleared neuro drain play that can ride shotgun with your Thrombolex playbook; $2.2M in, she’s ready to scale the exact commercial-stage device you pattern-matched at $50M. One call and we’ll see if this hits the multi-hundred-million strike zone you’re famed for. | “Clay, OrbiMed's $50M investment in Thrombolex shows your appetite for commercial-stage medtech - BrainSpace's FDA-cleared neuro device fits this profile perfectly...” | high |
| 16 | KCKevin Chu | F-Prime Capital | Principal | Kevin, your Cadence Neuroscience bet and the Farapulse $300M Boston Scientific exit prove you know how to ride shotgun on neuro devices right after 510(k). BrainSpace just cleared FDA for automated CSF/ICP and needs a partner who’s done the commercial sprint before; let’s lock the Series A before someone else grabs the allocation. | “Kevin, your neuromodulation investments at F-Prime, particularly Cadence Neuroscience, align directly with BrainSpace's automated CSF management technology...” | high |
| 17 | DRDuke Rohlen | Ajax Health | Founder, CEO, and Managing Partner | Duke has already ridden shotgun to five $1.7B+ device exits—he’ll spot the same quick-tuck path for Intellidrop’s fresh FDA 510(k) in the $3B neuro-ICP lane. Caitlin’s five-year Flex manufacturing playbook is primed for Ajax’s sprint-to-scale model; one call and we’ll map the next multi-hundred-million landing. | “Duke, with your track record of building and exiting 5 medtech companies to strategics, BrainSpace could be Ajax Health's next success story in neurocritical care...” | high |
| 18 | ODOlivier Delporte | SPRIG Equity | Venture Partner | You’ve already shepherded Miracor from FDA Breakthrough to $53M, and BrainSpace just hit 510(k) clearance on the same neurocritical-care money-maker—ride shotgun with Caitlin to turn her $2.2M seed into the next multi-hundred-million device exit. Let’s lock the Series A lead before the field floods. | “Olivier, your success securing FDA Breakthrough designation and $53M for Miracor resonates with BrainSpace's journey as we scale our FDA-cleared neuro technology...” | medium |
| 19 | KBKoen Van Breugel | Invest-NL/Coronet Ventures | Investment Manager | Koen backed €32M Xeltis and holds Harvard bioengineering chops—perfect co-pilot for our FDA-cleared Intellidrop as we scale neurocritical-care hardware. Dutch impact mandate meets Seattle manufacturing grit; let’s lock the Series A before the next hospital GPO sweep. | “Koen, your focus on medtech addressing healthcare staff shortages at Invest-NL aligns with how BrainSpace automates ICU workflows to reduce nursing burden...” | medium |
| 20 | LSLisa Suennen | American Heart Association Ventures | Managing Partner | $200M AHA brain-heart purse is built for FDA-cleared neuro devices like Intellidrop—ride shotgun with the Venture Valkyrie who’s already primed for the exact multi-hundred-million neurocritical exit. This Series A window closes fast; one call locks the lead. | “Lisa, AHA Ventures' focus on brain health innovation makes BrainSpace's automated CSF management system a natural fit for improving neurocritical care outcomes...” | medium |
data/lsi/l3_henry_star51.json · data/lsi/thesis_primitive_validation.json (Star51 thesis seed)
| # | Founder | Role | Opus Score | Cos | Why Star51 fit · Opus 4 | Link |
|---|---|---|---|---|---|---|
| #1 |  Marc Zemel mpID 3236 |
Chief Executive Officer | 9.5 | 0.458 | Marc’s FDA-cleared Argos monitor begs for Mayo’s cath-lab validation and Star51’s Rolodex of $300M tuck-ins; Tal already rode Corindus to J&J for $1.1B and Raymond’s Axonics hit $4B. We ride shotgun with the same strategics, primed for the exact multi-hundred-million exit—let’s tee this up at LSI USA ’26 before the strategics swarm. | |
| #2 |  Colby Holtshouse mpID 3098 |
Head Of Us Maternal Health Business Unit | 9.2 | 0.472 | She already delivered a $240M Organon exit from women’s health and is now steering May Health’s minimally-invasive PCOS device toward FDA; Star51’s Mayo-backed validation engine and $100M checkbook can compress that path and tee up the next nine-figure strategic. Let’s put her on the LSI ’26 stage and get the Mayo clinicians in the room this quarter—deal flow is warming. | |
| #3 |  Paul Molloy mpID 2705 |
— | 9.0 | 0.451 | 25-year operator who’s already banked Teleflex’s $55M VasoNova tuck-in and taken LMA public is now steering FDA-cleared ClearFlow and seed-stage Avvio—perfect ammo for Star51’s Mayo-backed validation engine and $100M Fund I. Ride shotgun with Tal, Raymond and the LSI network to turn his next device into a multi-hundred-million strategic exit—book the meeting now. | |
| #4 |  Declan Soden mpID 2593 |
— | 8.8 | 0.464 | 20-year electroporation vet with 500+ patients treated and €8.5M non-dilutive already in pocket; ePORE is the exact kind of Mayo-validated, fast-to-strategic tuck-in Star51 turns into $300M exits like Axonics. Let’s get you in front of Tal & Raymond before J&J or Boston Scientific beats us to the term. | |
| #5 |  Jeff Caputo mpID 1862 |
Founder & Chief Executive Officer | 8.5 | 0.440 | Four-in-one electrosurgery rig hits the same multi-hundred-million tuck-in radar that snagged Corindus and Axonics—Star51’s Mayo validation machine can de-risk FDA chatter and tee this up for Stryker or J&J before 2026. You’ve commercialized and exited once; we’ve got the $100M fund and the LSI podium—let’s ride shotgun and get this thing strategic-term-sheet-ready now. | |
| #6 |  Mark Wisniewski mpID 1702 |
Commercial Development, Business Operations, CFO | 8.3 | 0.445 | We ride shotgun with the CFO who just sheered a $450M Boston Scientific exit—Enterra’s FDA-approved gastroparesis stim is begging for Mayo’s validation and Star51’s top-5 strategic rolodex. $100M Fund I writes $0.5-5M seed-B checks; Tal already booked Corindus, Raymond took Axonics public—this is the multi-hundred-million replay. Let’s tee up a private LSI ’26 diligence room before the strategics circle. | |
| #7 |  Alan Lucas mpID 2347 |
Mentor & Judge | 8.0 | 0.439 | 25-year FDA assassin who’s shepherded 3 exits and mentored 200+ MIT/ MassChallenge teams now has two stealth devices ready for Mayo’s cath labs—perfect fodder for Star51’s $100M fund and J&J/Axonics Rolodex. Let’s put Tal’s Corindus playbook to work on a $5M seed before LSI ’26 judges see him. | |
| #8 |  Patrick O'Neill mpID 3384 |
Vice President, Strategic Partnerships | 7.8 | 0.449 | FDA Breakthrough-tagged QUTE-CE MRI is the exact “Mayo-ready” asset our $100M Star51 fund was built to catapult; ride shotgun with Tal/Cohen who already shepherded Corindus and Axonics to 9-figure even 10-figure exits. Let’s tee up a 30-min slot at LSI USA '26 and lock in clinical validation plus top-5 strategics before the next raise. | |
| #9 |  Craig Palmer mpID 2882 |
Commercial Officer | SVP US Sales | 7.5 | 0.441 | Barostim’s FDA nod and $300M+ revenue ramp scream the exact Mayo-validated, Series-B-ready asset Henry hunts for. Riding shotgun with Star51’s $100M Mayo-anchored purse and Tal’s Corindus exit playbook, we can prime a J&J or Axonics tuck-in before LSI ’26. Let’s lock the meeting now. | |
| #10 |  Adrian Lam mpID 1492 |
Chief Executive Officer | 7.2 | 0.459 | Ride shotgun with the guy who turned Genesis into a unicorn in 14 months and already has FDA-cleared AI cardio tech scaling through CorVista—Mayo’s cath-lab validation plus Star51’s top-5 strategics ($300M J&J tuck-in playbook) prime this for the exact multi-hundred-million exit. LSI USA ’26 is the only room where this deal gets wired; let’s lock the first look before the strategies swarm. | |
| #11 |  Jayon Wang mpID 2912 |
Director | 7.0 | 0.469 | Jayon just shepherded X-COR’s ECCO2R device through $2.8M seed and is hunting the next FDA-cleared platform; Star51’s Mayo-backed validation engine and $100M checkbook ride shotgun from first-in-man to J&J-style tuck-in. We should sync at LSI USA ’26 before he locks the Series A syndicate—his mechanical-to-clinical playbook is primed for a nine-figure exit. | |
| #12 | Azin Parhizgar mpID 2510 |
EVP - Emerging Ventures | 6.8 | 0.453 | Ride shotgun with the cardiologist who already delivered Boston Sci a $270M tuck-in on Sentinel—Mayo validation plus Star51’s J&J/BSX speed-dial primed for the next multi-hundred-million exit. LSI USA ’26 table is set; your 30-year CV track record is the headliner we need to book now. | |
| #13 |  Gopal Chopra mpID 3609 |
Vice President | 6.5 | 0.459 | Ride shotgun with a neurosurgeon-banker who banked $2B Arrow-Teleflex and already built a HIPAA platform; Star51’s Mayo validation + $100M Fund I is primed to catapult his next robotic-surgery play into a top-5 strategics tuck-in. Book the LSI ‘26 slot today—FDA-cleared or near-cleared, this match needs to happen now. | |
| #14 |  Jarret Fass mpID 3611 |
Board Member - Advamed Accel | 6.2 | 0.450 | Ride shotgun with the guy who’s already banked four med-tech builds and sold Hospital IQ to Bain—exactly the repeat founder who can turn Mayo’s clinical data into a $300M J&J tuck-in. Star51’s $100M Fund I writes $5M first checks and pipes straight to Tal’s Corindus rolodex; let’s tee up your next FDA-cleared winner at LSI USA ’26. | |
| #15 |  Marit Slawson mpID 1465 |
President | 6.0 | 0.447 | Bright’s 6× headcount growth + 20–30% YoY revenue screams FDA-savvy CRO that can slam Mayo-validated devices through pivotal trials faster than anyone in the Midwest. Ride shotgun with Henry to turn the next $5M Star51 check into a $300M J&J/Axonics-style tuck-in—let’s tee this up at LSI USA ’26 before the strategics swarm. |
| # | Name | Role | Company | Why this pick · Opus 4 |
|---|---|---|---|---|
| 1 |  Esra Roan | Co-founder and CEO |  SOMAVAC Medical Solutions | She’s raised $3.1M, holds a US patent on SmartSuction, and just navigated FDA clearance—exactly the lived IP gauntlet LSI’s stage demands. Slide her into the empty seat and give the room the only operator voice that’s actually survived diligence and term-sheet trenches. |
| 2 | EMEmily Mirro ⚠ | President And Co-Founder | SynchNeuro, Inc. | President Mirro has lived the IP gauntlet as a two-time founder in neuro-dev, where every electrode claim is a deal-killer or deal-maker; she’s already convinced both VCs and strategics to write checks while patents were still pending. That battle-tested voice is the exact counterweight the all-male investor table still needs—let’s lock her in before LSI finalizes the board. |
| 3 |  Yvonne Bokelman | Chief Executive Officer |  Alyve Medical | Medtronic veteran who steered $300M+ ortho P&L through multiple acquirer screens, she’s living the IP firefight while scaling Alyve’s shoulder-pacemaker platform—exactly the operator war story LSI’s male-heavy investor panel is missing. Lock her her seat before agenda goes final next week. |
| 4 |  Anaelle Blachon | CEO and R&D Director |  Extremis Robotics | Freshly-minted patent-holder who just convinced investors to price her IP at a €450K seed round can ride shotgun with the boys and tell the room what diligence actually feels like when the cap table is on the line. Grab her before the program locks Friday. |
| 5 |  Lori Chmura | Chief Executive Officer |  Nyra Medical | She’s steered two exits through IP gauntlets—most recently Dune Medical’s sale—and turned around J&J’s $250M Cordis while keeping patents bulletproof. Lived operator view plus battle-tested M&A scars gives the panel the only voice that isn’t capital or counsel. Lock her now before LSI prints the final roster. |
sex on 676 previously-unlabeled LSI people. Initial re-run of the production endpoint POST /robert-lab/o1-ip-panel returned cohort expanded 138 → 165 (+27 newly identifiable women) but 0 rankings across 3 attempts — the cohort filter works but the Groq-based rationale step silently drops on the reshuffled bio set. Diagnosis: endpoint still uses groq/llama-3.3-70b-versatile (not Opus as planned Apr 20), and the JSON-fence strip isn't hardened against the reshuffled top-N. Mitigation: bypassed the server and implemented Mark's PDF recipe client-side — gender_guesser for female filter, regex title gate for operators, direct call to Claude Opus 4 via OpenRouter (no fence issues). Fresh top-5 below reflects the corrected, expanded, gender-accurate cohort.
anthropic/claude-opus-4 via OpenRouter · Artifacts: data/lsi/o1_v3_client_side.json · data/lsi/o1_client_pipeline.py
| # | Name | Title | Company | Why this speaker · Opus 4 | Conf |
|---|---|---|---|---|---|
| 1 | GNGabriele Niederauer | CEO & Co-Founder | Freyya, Inc. | She’s taken four devices from napkin sketch to FDA clearance and a tuck-in sale—Merit just bought her last one—so she can speak to how bruised patents survive DD and still fetch nine-figure checks. Grab her before LSI locks the final run-of-show. | high |
| 2 | BEBreanne Everett | CEO & Co-Founder | Orpyx Medical Technologies | Breanne closed $27.9M, built 130-person Orpyx and steered the SI Sensory Insoles through 86% ulcer-recurrence data that underwrote the company’s IP fortress—exactly the lived cap-table-to-exit war story LSI’s all-male investor panel is missing. She’ll ride shotgun with the room, not lecture it, on how patents survive diligence when the check hits. Grab her before the calendar locks. | medium |
| 3 | CACarolina Aguilar | CEO & Co-Founder | INBRAIN Neuroelectronics | She just steered INBRAIN through $68M in raises and FDA Breakthrough nod for graphene BCIs—exactly the operator scar-tissue LSI’s male-heavy IP panel lacks. Her $140M Medtronic P&L and lived M&A prep give founders real-world IP war stories. Grab her before the agenda locks. | medium |
| 4 | TSTeri Sirset | Co-Founder, President & CEO | DASI Simulations | Teri just inked 11 hospital deals and a $16M raise while steering FDA-cleared Digital Twin software through due-diligence hell—exactly the operator war story LSI’s male-heavy IP panel is missing. Grab her before the program locks next week. | medium |
| 5 | ABAmy Baxter | Founder & CEO | Pain Care Labs | Ride shotgun with the physician-founder who turned 12 patents into 45M+ hospital touches and a worldwide roll-up—no VC, no lawyer, just battle-scarred operator. LSI stage is 95% male money talk; one female founder who shipped product across 27 countries flips the room and gives founders the map. Book her seat today—deal heat is now. | high |
| # | Name | Title | Signal | Why this LP · Opus 4 |
|---|---|---|---|---|
| 1 |  Jason Topolosky | Vice President, Business Development & Strategy, Trauma & Extremities | operator_exit | Led Stryker's landmark $5.4 billion Wright Medical acquisition and spent 19 years at the medtech giant driving M&A strategy. Now CBO at OsteoCentric Technologies with board advisor roles at multiple medtech startups, making him a perfect operator-exit LP with deep pockets and industry connections. |
| 2 |  Peter Boyd | Senior Director, Strategy - Harpoon Integration | operator_exit | Co-founded Harpoon Medical and negotiated its $100M exit to Edwards Lifesciences in 2017 with 100%+ IRR for investors. Currently CEO of multiple medtech startups (ReGelTec, Sonnest) while serving as Senior Director at Edwards, embodying the ideal operator-exit profile with proven wealth creation. |
| 3 | Azin Parhizgar | Executive Vice President - Emerging Ventures | operator_exit | Led Claret Medical as President/CEO to $270M acquisition by Boston Scientific after achieving 60% TAVR procedure adoption. Now US Managing Director at 415 Capital with 30+ years driving billion-dollar cardiovascular exits, perfectly aligned as both operator-exit and potential co-investor. |
| 4 |  Omar Ishrak | President And Chief Executive Officer, Ge Healthcare Systems | operator_exit | Engineered Medtronic's $42.9 billion Covidien acquisition and created $90 billion in market value as CEO from 2011-2020. Currently chairs Qubit Health Capital and serves on Cleveland Clinic's board, representing the ultimate operator-exit profile with massive wealth and Mayo Clinic synergies. |
| 5 |  Michael Whitman | operator_exit | Founded Power Medical Interventions, took it public on NASDAQ in 2007, and sold to Covidien for $64 million in 2009. Currently CEO of Micro Interventional Devices with 55+ patents and 40 years in healthcare, exemplifying the serial entrepreneur operator-exit profile. | |
| 6 |  Darren Sherman | President, Chief Operating Officer, Founder And Member Of Board Of Directors | operator_exit | Founded Orchestra BioMed and led its January 2023 NASDAQ listing while holding 75+ US patents. Previously first employee at Revivant Corp developing AutoPulse CPR device through acquisition by Zoll Medical, demonstrating repeat founder success with multiple exits. |
| 7 |  Samantha Surrey | hnw_founder | Founder of Surrey Capital Partners and Co-Founder of Decision Medical Ventures, having managed $2.5 billion in transactions at GlaxoSmithKline and a $750 million fund at Bioscience Managers. Serves on boards of AiM Medical Robotics and Outlook Surgical, fitting the HNW founder profile with LP experience. | |
| 8 |  Mirren Mandalia | Vice President, New Growth Platforms, Business Development, Johnson & Johnson Medtech | operator_exit | Played key leadership role in J&J MedTech's $13.1 billion Shockwave Medical acquisition in April 2024. Now VP Corporate Development at LivaNova leading M&A and venture investments, combining operator-exit credentials with active dealmaking in cardiovascular space. |
| 9 |  Akel Akel | Head Of Business Development, Medtech At Ge Healthcare | operator_exit | Heads Business Development for GE HealthCare's MedTech division, overseeing M&A for a $5 billion business since 2016. With nearly two decades in finance and corporate development plus board treasurer role, represents strategic operator-exit profile with acquisition authority. |
| 10 |  Ilya Trakhtenberg | Managing Director & Partner | prior_lp | Managing Director at L.E.K. Consulting specializing in MedTech strategy for 15+ years, advising corporate and PE clients on growth and M&A. Founded L.E.K.'s MedTech Launch Center of Excellence and co-authored 'Predictable Winners', fitting prior-LP profile with deep sector expertise. |
is_angel label coverage — pre-ranker compensated by layering exit-bio regex (IPO, acquired, sold to, NASDAQ) over strong-title filter.
Orthogonal signal to cosine+Opus ranking. 6 sub-scores from bio text → weighted composite (exit 0.35 · board 0.20 · family-office 0.15 · public-market 0.10 · VC 0.10 · patents 0.10). Validates operator-exit LPs with explicit wealth-creation evidence.
| HNW # | Name | Score | Exit $ | Board | VC | Opus # | Δ |
|---|---|---|---|---|---|---|---|
| 1 | Omar Ishrak | 0.550 | $90,000M | 3 | 0 | 4 | ▲ 3 |
| 2 | Terri Burke | 0.543 | $250M | 1 | 2 | — | new |
| 3 | Azin Parhizgar | 0.472 | $270M | 1 | 3 | 3 | — |
| 4 | Akel Akel | 0.467 | $5,000M | 1 | 1 | 9 | ▲ 5 |
| 5 |  Deepa Rich | 0.435 | $556M | 0 | 1 | — | new |
| 6 | Jason Topolosky | 0.417 | $5,400M | 1 | 0 | 1 | ▼ 5 |
| 7 | Samantha Surrey | 0.383 | — | 2 | 2 | 7 | — |
| 8 | Mirren Mandalia | 0.350 | $13,100M | 0 | 0 | 8 | — |
| 9 | Peter Boyd | 0.339 | $100M | 0 | 0 | 2 | ▼ 7 |
| 10 |  Adam Wollowick | 0.298 | $1,400M | 0 | 0 | — | new |
/tmp/l1-luc/hnw_proxy.py · 20 cands scored · run time <100ms.
operator_exit, hnw_passion, prior_fund_lp, strategic_anchor, board_seats) and a Star51-differentiation-aware opener per candidate.data/lsi/o2_v2_full_deck.json · data/lsi/o2_client_pipeline.py
| # | Name | Title | Signal | Evidence | Why this LP · Opus 4 | Henry's opener | Conf |
|---|---|---|---|---|---|---|---|
| 1 | JKJoe Kiani | Founder, Chairman & Chief Executive Officer | operator_exit | Founded Masimo, grew to $2B global enterprise | You minted $90B in value at Medtronic and already ride shotgun with Blackstone Life Sciences; Star51’s first-close Mayo-anchored $100M fund lets you co-invest in the same device plays you once acquired. Let’s put that Covidien-grade vision to work—calendar us for the week after Thanksgiving. | “Joe, your journey building Masimo to $2B resonates with our Corindus-to-Siemens playbook—would love to share how Star51's Mayo anchor could accelerate your portfolio companies.” | high |
| 2 | JMJosh Makower | Professor Of Medicine / Bioengineering, Director / Co-Founder, Stanford Mussalle | operator_exit | Created 11 companies including Acclarent ($785M to J&J) and NeoTract (up to $1.1B) | You’ve already steered a $5.4B Stryker–Wright blockbuster and sit on three emerging-device boards; ride shotgun with Mayo and the same strategics to seed the next wave of $300M–$1B exits. Star51’s first-close in April is capped at $200M—your operator muscle and deal DNA fill one of the last seats. | “Josh, your ExploraMed model creating 11 exits mirrors our integrated platform—Mayo's clinical validation plus LSI's 20-year data could supercharge your next innovations.” | high |
| 3 | SMSteven Mickelsen | Founder | operator_exit | Founded Farapulse, acquired by Boston Scientific for ~$800M | You’ve already moved $2.5B across GSK pipelines deals and $750M funds—ride shotgun with Mayo Clinic and the Corindus/Axonics crew who know every $300M tuck-in from here to J&J. First close is April ’26; co-invest sidecars are filling fast, so lock the slot now before the strategic table is gone. | “Steven, your Farapulse exit to Boston Scientific exemplifies our Axonics playbook—Raymond Cohen's experience could help your next PFA ventures scale faster.” | high |
| 4 | SHScott Huennekens | President & Chief Executive Officer, Board Member | operator_exit | Led Volcano Corporation to $1.2 billion acquisition by Philips | You've spent 15 years shepherding $2–50B medtech deals at L.E.K.; ride shotgun with the only $100M fund anchored by Mayo Clinic and a top-5 strategic to turn that pattern-recognition into your own equity upside. First close is April—let’s put your name on the cap table before the allocation disappears. | “Scott, your Volcano-to-Philips journey parallels our Corindus story—Star51's Mayo validation engine could accelerate your portfolio companies' clinical adoption.” | high |
| 5 | DHDaniel Hawkins | Chief Executive Officer | operator_exit | Founded Shockwave Medical, $13.1 billion acquisition by J&J | You’ve bankrolled every $1B+ medtech exit out of Citi; ride shotgun with the only fund that turns those same deals into 3-5x DPI by stapling Mayo Clinic’s R&D pipeline to the strategics you already seat on the buy-side. First-close April, $100k min—let’s get you in before the operator table fills. | “Daniel, your Shockwave exit redefined medtech M&A—our strategic anchors and LSI's global pipeline could help Vista AI follow a similar trajectory.” | high |
| 6 | ASAmr Salahieh | President & Chief Executive Officer | operator_exit | Founded Sadra Medical acquired for $450M, raised $800M across portfolio | You just delivered Harpoon’s $100M Edwards tuck-in and are running two more device plays—ride shotgun with the only fund where Mayo Clinic and a top-5 medtech strategic co-invest every deal, same table Tal used to sell Corindus for $1.1B. First close April ’26, $100k min check, operator LPs only—lock your slot before it’s gone. | “Amr, Shifamed's innovation model mirrors our vision—combining your Silicon Valley engine with Mayo's clinical validation could create unprecedented opportunities.” | high |
| 7 | MMMike Mahoney | Chairman And Chief Executive Officer Boston Scientific | strategic_anchor | CEO Boston Scientific, grew market cap from $7B to $148B | You just banked a $64M Covidien exit and still own 55 patents on catheter wizardry—ride shotgun with Tal & Raymond who already punched Corindus and Axonics through nine-figure doors while Mayo writes the next referral scripts. Star51’s first close is April ’26; your check plants you inside every deal the strategics co-invest in. | “Mike, your Boston Scientific transformation showcases strategic vision—Star51's Mayo-anchored platform could surface your next Axonics or Farapulse earlier.” | high |
| 8 | PHPeter Hebert | Co-Founder & Partner | prior_fund_lp | Co-founded Lux Capital ($7B AUM), led Auris exit to J&J for up to $6B | You just rode the Sentinel to Boston’s $270M tuck-in and still chair CVPath and Protembis—Star51’s Mayo-backed first close gives you the same operator-access to co-invest in the next cerebral, peripheral or neurovascular win before April. Let’s wire you in. | “Peter, your Auris-to-J&J success demonstrates robotics foresight—our LSI data advantage identifies similar breakthroughs 2-3 years before mainstream funds.” | high |
| 9 | DZDarshana Zaveri | prior_fund_lp | Founder Catalyst Health Ventures with $150M+ AUM | Darren just took Orchestra BioMed public and still holds the cap-table chops; we’re building a $100M fund anchored by Mayo Clinic and the same strategics he already partners with. Ride shotgun with Tal, Adam and Raymond on the next Corindus-style exit—first close April 2026, your seat’s open now. | “Darshana, your Catalyst portfolio in interventional oncology aligns perfectly—our Mayo anchor provides unique clinical validation your companies need.” | high | |
| 10 | JMJoe Mullings | Chief Executive Officer & Founder | hnw_passion | 9,000+ placements for 900+ companies including J&J, Medtronic | You just shepherded J&J’s $13.B Shockwave take-out and now sit on LivaNova’s deal-sourcing throttle—ride shotgun with the only $100M fund where Mayo Clinic and top-5 strategics co-invest side-by-side with operators like you. First close April ’26; lock in your seat before the allocation’s gone. | “Joe, your 9,000 placements shaped medtech leadership—Star51's platform connects that talent network with Mayo-validated innovations.” | high |
| 11 | ZSZack Scott | prior_fund_lp | GP at Norwest, co-founded Revelation Partners, iRhythm $107M IPO | You’ve papered the $2.2 B Septerna/Novo deal and countless device exits—now ride shotgun with Mayo Clinic and the Corindus → Siemens crew to write yourself into their next $300 M tuck-in. First close April ’26, $100 k minimum, and your term-sheet IQ instantly vets every portfolio deal—let’s lock it in this quarter. | “Zack, your physician-to-investor journey mirrors our clinical-first approach—Mayo's validation plus your Norwest portfolio could create powerful synergies.” | high | |
| 12 | HGHanson Gifford | Chief Executive Officer / Managing Partner | operator_exit | Co-founded Ardian acquired by Medtronic for up to $1.3B, 370+ patents | You’ve steered $5B of GE Medtech M&A and know every bolt-on left on the board—let’s park your next win next to Mayo and Siemens-Corindus-style $100M exits inside Star51’s first $100M fund. First close April ’26, operator checks start at $100k—coffee this month locks your seat before the anchor LPs fill it. | “Hanson, The Foundry's innovation engine parallels our vision—combining your model with Mayo's clinical insights could accelerate breakthrough development.” | high |
| 13 | ACAndrew Cleeland | Member, Industry Advisory Board | operator_exit | Led Ardian to $1.3B Medtronic acquisition, Twelve to $458M exit | You just closed a $25M A for DeepSight’s FDA-cleared NeedleVue—exactly the kind of real-time imaging play Tal & Raymond will be stacking into Star51’s tuck-in pipeline beside Mayo. Ride shotgun with the Axonics IPO crew and the Corindus crew who already banked a Siemens exit, then co-strike the next $300M device sale together. | “Andrew, your $1.8B in cardiovascular exits aligns with our thesis—Star51's strategic anchors could accelerate your Fogarty portfolio companies.” | high |
| 14 | Omar Ishrak | President And Chief Executive Officer, Ge Healthcare Systems | hnw_passion | CEO Medtronic 2011-2020, engineered $42.9B Covidien acquisition | You’ve already banked the $250M Harpoon exit and sit on Intuitive’s $250M purse—now ride shotgun with Mayo Clinic and the same crew that just steered Corindus into Siemens to do it again at twice the speed. First close is April 2026; reserve your seat before the operator allocation fills. | “Omar, your Medtronic transformation and Covidien integration exemplifies strategic vision—Star51's Mayo partnership offers similar transformational opportunities.” | high |
| 15 | WDWilliam Dai | prior_fund_lp | Founded ShangBay Capital, raised $200M across 3 funds, 72 portfolio companies | You just spent two decades shaping cardiac tech for the same strategics we ride shotgun with—Mayo and top-5 device giants—so co-investing in Star51’s $100M first-close vehicle is the logical next play. Drop a $100k min check beside Tal’s Corindus → Siemens exit crew and let’s turn your EP intel into the next $300M tuck-in before April 2026. | “William, your ShangBay portfolio demonstrates medtech conviction—our LSI partnership provides proprietary deal flow your LPs would value.” | high | |
| 16 | Paul Molloy | operator_exit | Led VasoNova to $55M Teleflex acquisition, LMA to IPO and acquisition | You’ve already surfed Questa’s medtech winners and know the expansion-stage playbook—ride shotgun with Mayo-powered Star51 and co-invest the exact $100M+ tuck-ins you used to chase from the buy-side. First close April 2026, your check books the seat before strategics fill it. | “Paul, your clinical-to-CEO journey and VasoNova exit resonate with our model—Mayo's validation could accelerate ClearFlow's trajectory.” | high | |
| 17 | ASAkhil Saklecha | Chief Executive Officer And Co-Founder | hnw_passion | Former CSO Danaher $11B diagnostics, GP Artiman Ventures | You just shepherded a $700M global immunoassay line at Roche—ride shotgun with Tal & Raymond on the next Mayo-curated diagnostic hit while the $200M Star51 vehicle is still open to scale. First close April 2026; co-invest sidecars primed for the exact multi-hundred-million strategic tuck-in you’ve delivered before. | “Akhil, your Danaher scale and Cleveland Clinic Ventures experience parallels our integrated model—Mayo's anchor could enhance your portfolio approach.” | medium |
| 18 | RCRenard Charity | Senior Vice President Marketing, Long Term Care | National Elder Care Thought Le | board_seats | Managing Partner Fletcher Spaght managing $130M+, board member HistoSonics | You’ve sized up 15k+ devices across surgical, resp, and Dx; we’re wiring Mayo + Siemens/Axonics veterans into the same $100–200M pool so operators like you ride shotgun on the next Corindus-style exit. First close April—let’s get you a seat before the strategics fill it. | “Renard, your Fletcher Spaght Ventures portfolio aligns with our thesis—Star51's Mayo validation could strengthen your robotic surgery investments.” | medium |
| 19 | KDKyle Dempsey | prior_fund_lp | Partner at MVM Partners, MD/MBA Harvard, led $14M MDxHealth stake | You’ve already banked two ortho exits and are now steering the 50-year-hip Garland rocket—ride shotgun with Tal & Raymond who just punched Corindus into Siemens and Axonics onto NASDAQ, while Mayo scripts the next playbook. $100M first-close April 2026, operator checks start at $100K—let’s place your chips inside the only fund built to co-invest with the strategics who’ll buy Garland. | “Kyle, your MVM medtech portfolio could benefit from our Mayo clinical validation—particularly for your women's health and cardiology investments.” | medium | |
| 20 | GBGerry Brunk | prior_fund_lp | Co-founder Lumira Ventures, led $220M Fund IV raise, exits include MAKO to Stryker | You’ve already banked $1.4B K2M and $500M Mobius wins for Stryker—ride shotgun with the only fund where Mayo Clinic and the same top- in the room, primed for the exact multi-hundred-million tuck-ins you’ll source next. First close April ’26; seats disappear faster than PE can overpay. | “Gerry, your MAKO-to-Stryker success shows orthopedic foresight—our LSI data identifies similar robotic opportunities years before market consensus.” | medium |